Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Merck-Viralytics Deal: Just Doubling Down On Keytruda - Bloomberg

2018-02-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (54-0)

Tracking Tweedy Browne Portfolio - Q4 2017 Update

2018-02-21 seekingalpha
The largest five individual stock positions are Cisco Systems, Berkshire Hathaway, Baidu Inc., Johnson & Johnson, and Alphabet and they account for ~45% of the portfolio. (408-1)

BioXcel Therapeutics Seeks $69 Million U.S. IPO

2018-02-16 seekingalpha
The firm is using the advanced data and AI technologies of its parent company to improve its drug development efforts. (381-3)

PRESS DIGEST- Wall Street Journal - Feb 16

2018-02-16 reuters
Feb 16 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. (73-0)

PRESS DIGEST- Financial Times - Feb 16

2018-02-16 reuters
Feb 16 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. (56-0)

Roche to Acquire Healthcare-Software Company Flatiron for $1.9 Billion - WSJ

2018-02-16 wsj
Pharmaceuticals firm Roche Holding AG has agreed to buy the shares it doesn’t already own of Flatiron Health Inc., an oncology software company, for $1.9 billion, the companies said Thursday. (15-0)

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

2018-02-15 reuters
(Reuters) - Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of the privately held U.S. cancer data company Flatiron Health Inc for $1.9 billion to speed up development and delivery of breakthrough medicines for cancer patients. (109-1)

ECA2018-21 - Information Regarding the Tender Offer of Ignyta, Inc. (RXDX)

2018-02-09 nasdaqtrader
The tender offer by Roche Holding AG to acquire all of the outstanding shares of Ignyta, Inc. (RXDX) is scheduled to expire at midnight ET on February 7, 2018. The subsequent merger is expected to close February 8, 2018. The details are as follows: (15-0)

New Drugs Are Coming to Fight Nasty Flu Seasons - Bloomberg

2018-02-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (43-1)

The Alzheimer’s Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

2018-02-08 wire.kapitall
"Age is just a number, not a state of mind or a reason for any type of particular behavior." (329-1)

Sanofi Earnings: Deal Desperation Now Looks Even Worse - Bloomberg

2018-02-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (48-0)

Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates

2018-02-07 zacks
Seattle Genetics, Inc. (SGEN - Free Report) reported a loss of 41 cents per share for the fourth quarter of 2017, narrower than the Zacks Consensus Estimate of 43 cents but wider than the year-ago quarter loss of 39 cents per share. (47-0)

Array's Melanoma Combo Shows Positive Overall Survival Data

2018-02-07 zacks
Array BioPharma Inc.'s (ARRY - Free Report) shares increased more than 15% on Feb 6 after it announced encouraging overall survival (OS) data from a pivotal phase III study evaluating COMBO450, a combination medicine of binimetinib and encorafenib. Array along with partner Pierre Fabre have developed the combo therapy for treating patients with BRAF-mutant advanced, unresectable or metastatic melanoma. (275-1)

Array melanoma drugs show significant survival vs Roche drug in study - Channel NewsAsia

2018-02-06 channelnewsasia
REUTERS: A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday. (265-0)

Array melanoma drugs show significant survival vs Roche drug in study

2018-02-06 reuters
(Reuters) - A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday. (265-0)


CUSIP: 771195104